UBS Group
SLS icon

UBS Group’s SELLAS Life Sciences SLS Stock Holding History

UBS Group’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5M Buy
1,252,757
+507,338
+68% +$3.5M ﹤0.01% 2771
2026
Q1 		$3.15M Buy
745,419
+696,692
+1,430% +$3.12M ﹤0.01% 4547
2025
Q4 		$184K Sell
48,727
-36,262
-43% -$70.5K ﹤0.01% 6621
2025
Q3 		$137K Sell
84,989
-224,698
-73% -$400K ﹤0.01% 6907
2025
Q2 		$678K Buy
309,687
+247,456
+398% +$380K ﹤0.01% 5762
2025
Q1 		$67.2K Sell
62,231
-65,590
-51% -$77.9K ﹤0.01% 7352
2024
Q4 		$133K Buy
+127,821
New +$146K ﹤0.01% 6697
2023
Q4 		– Sell
-26
Closed -$43 – 9834
2023
Q3 		$43 Buy
+26
New +$41 ﹤0.01% 9031
2022
Q4 		– Sell
-1,359
Closed -$3K – 11110
2022
Q3 		$3K Buy
+1,359
New +$3.75K ﹤0.01% 9576
2019
Q4 		– Sell
-2,410
Closed -$15K – 8372
2019
Q3 		$15K Buy
+2,410
New +$17.8K ﹤0.01% 6915
2019
Q2 		– Hold
0
– – – 8129
2019
Q1 		– Sell
-99
Closed -$6.88K – 8123
2018
Q4 		$6K Buy
+99
New +$7.67K ﹤0.01% 7490
2018
Q3 		– Sell
-35
Closed -$2.42K – 8243
2018
Q2 		$6K Buy
35
+24
+218% +$6.58K ﹤0.01% 7417
2018
Q1 		$2K Sell
11
-6
-35% -$1.71K ﹤0.01% 7550
2017
Q4 		$7K Buy
17
+11
+183% +$5.32K ﹤0.01% 7241
2017
Q3 		$3K Buy
+6
New +$3.96K ﹤0.01% 7404
2017
Q2 		– Sell
-15
Closed -$13.1K – 7952
2017
Q1 		$14K Buy
15
+14
+1,400% +$23.2K ﹤0.01% 6408
2016
Q4 		$3K Buy
+1
New +$5.82K ﹤0.01% 7427

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's SLS Position: Q2 2026 in Review

UBS Group increased its SELLAS Life Sciences (SLS) stake by 68% in Q2 2026, buying an estimated $3.5M and bringing the position to 1,252,757 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

UBS Group first reported a position in SLS in Q4 2016 and has held it in 17 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • UBS Group held 1,252,757 shares of SELLAS Life Sciences worth $18.5M as of Q2 2026.
  • UBS Group bought 507,338 SELLAS Life Sciences shares in Q2 2026, an estimated $3.5M.
  • SELLAS Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2771 holding.
  • UBS Group first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 17 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.